CD40 and neoplasm: Similarly, CD40 agonists activate APCs, enhancing tumor antigen presentation and T cell stimulation, leading to stronger anti-tumor immune responses.510,511 The interaction between CD40 and its ligand, CD40L, is crucial for the maturation of dendritic cells, enabling more effective antigen presentation and sustained T cell responses.512 Moreover, combining CD40 agonists with other therapies, such as chemotherapy or checkpoint inhibitors, has shown promise in improving therapeutic outcomes by maximizing immune activation and overcoming tumor evasion.510,513